Acalabrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.670
CATDS
0.044
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Acalabrutinib. Strongest target: ERBB4_HER4 at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 99.9% | 0.1% |
| 2 | BTK | 95.9% | 4.1% |
| 3 | TEC | 87.4% | 12.6% |
| 4 | BMX_ETK | 86.6% | 13.4% |
| 5 | TXK | 58.7% | 41.3% |
| 6 | ARAF | 58.3% | 41.7% |
| 7 | BRK | 52.0% | 48.0% |
| 8 | LIMK1 | 39.9% | 60.1% |
| 9 | YES_YES1 | 39.9% | 60.1% |
| 10 | CDK9_CYCLIN_T2 | 30.1% | 69.9% |
| 11 | MEK3 | 24.2% | 75.8% |
| 12 | RIPK2 | 23.3% | 76.7% |
| 13 | ERN1_IRE1 | 20.1% | 79.9% |
| 14 | BLK | 19.9% | 80.1% |
| 15 | DDR1 | 19.1% | 80.9% |
| 16 | AURORA_B | 17.9% | 82.1% |
| 17 | PKCTHETA | 17.9% | 82.1% |
| 18 | MKK6 | 17.6% | 82.4% |
| 19 | CDK9_CYCLIN_T1 | 17.1% | 82.9% |
| 20 | C_SRC | 16.9% | 83.1% |
Selectivity landscape
Where Acalabrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Acalabrutinib.
Annotations
Sign in to read and post annotations.
Loading…